ST. JOSEPH, Mich., Oct. 24 /PRNewswire/ -- GeneGo, Inc., a leading provider of software and databases for systems biology, today announced the launch of two new products, MapEditor and MetaLink. The products are add-on modules in the MetaCore environment designed for integration, editing and mapping custom interactions data.
MapEditor enables the generation of custom pathway maps starting from scratch, converting a network in to a pathway map or editing one of the existing 500 proprietary maps from MetaCore. This allows GeneGo customers to develop NEW pathway maps based on their proprietary data that is only accessible to their company. GeneGo’s maps are becoming the industry standard and are currently widely available via the iPath(TM) Online BioAtlas from Invitrogen at www.invitrogen.com/ipath.
MetaLink allows users to batch upload their own protein association data produced by yeast-two-hybrid screens, gene co-expression, pull-down assays, text mining and other methods in MetaCore and build networks on the fly overlaying their interactions in the context of manually curated interactions. The accompanying gene expression and other molecular omics data can be mapped and prioritized on the resulting customized networks.
“MapEditor and MetaLink were developed in conjunction with our pharmaceutical customers, who needed customization tools to deal with their proprietary experimental interactions data not yet reported in the literature,” said Julie Bryant, Vice President of Business Development at GeneGo. “The new products round up our customization suite of tools which also includes PathwayEditor, launched two years ago. With these additions, the MetaCore platform has become a truly universal environment for functional data mining, capable of handling analysis of any type of molecular omics data and gene/protein association data. The main functional blocks in MetaCore, canonical maps and networks are now completely editable, seamlessly integrated and internally consistent.”
About GeneGo
GeneGo develops systems biology technology for life science research. The original computational platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, siRNA and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 4.1, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company’s web site at www.genego.com.
MetaCore(TM), MetaBase(TM) MapEditor(TM), MetaLink(TM) and MetaDrug(TM) are trademarks of GeneGo, Inc.
GeneGo, Inc.
CONTACT: Julie Bryant, VP Business Development and Marketing of GeneGo,Inc., +1-858-756-7996, julie@genego.com
